Eli Lilly execs have been thinking about the longterm effects of the pandemic and damage control. Here’s what they believe
Like a lot of Big Pharma outfits, Eli Lilly has some interesting projects going on for Covid-19. They have an early-stage antibody program in play with a partner, taken Olumiant and started work to see if it could help coronavirus patients. And they’ve mounted an ambitious effort to do local testing in their home base of Indianapolis, while being one of the first of the major players to outline work-at-home rules to keep the virus from spreading in-house.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,700+ biopharma pros reading Endpoints daily — and it's free.